Announcement on Holding Subsidiary's Progress in Drug Clinical Trials
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Holding Subsidiary's Progress in Drug Clinical Trials
Filed with SSE ·
6ix hasn’t read this filing yet.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on 6ix
Earlier from Shanghai Fosun Pharmaceutical (Group)
- Announcement on Completion of 2022 Non-public Offering Funded Projects and Closure of Special Accounts
- Announcement on Reply to Shanghai Stock Exchange's "Letter of Regulation in Outward Investment"
- Announcement on Signing Cooperation and Option Agreement by Holding Subsidiary
- Announcement on Outward Investment
- Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement
Later from Shanghai Fosun Pharmaceutical (Group)
- Announcement on Progress in Participating in the Establishment of Private Equity Investment Fund
- Announcement on Completing Private Investment Fund Filing for Subscribed Equity Investment Fund
- Announcement on Progress in Implementation of the Incentive Plan by a Holding Subsidiary
- Announcement on Completion of Filing with China Securities Regulatory Commission for Application for Full Circulation of Domestic Unlisted Shares of Holding Subsidiary
- Announcement on Resolutions of the 22nd (Extraordinary) Meeting of the 10th Board of Directors
Follow Shanghai Fosun Pharmaceutical (Group) into a list and get an email when it puts out news.
Follow Shanghai Fosun Pharmaceutical (Group)